Fennec Pharmaceuticals Hits Day High with 13.96% Surge in Stock Price

Fennec Pharmaceuticals, Inc. has experienced a significant uptick in its stock performance, gaining 13.96% on June 23, 2026. The stock reached an intraday high of CAD 14.98, reflecting strong market activity. Over the past week, Fennec has outperformed the S&P/TSX 60, with a weekly gain of 15.13% compared to the index's decline of 0.66%. In terms of annual performance, Fennec Pharmaceuticals has shown a robust increase of 35.65%, surpassing the S&P/TSX 60's return of 29.8%. Year-to-date, the company has achieved a remarkable 37.83% gain, significantly higher than the index's 10.52%. The company reported impressive net sales of CAD 20.72 million, marking a 65.05% increase. Additionally, cash and equivalents reached CAD 106.5 million, indicating a solid financial position. Despite these positive indicators, Fennec's stock has underperformed the market over the last year, generating a return of 19.03%. The company maintains a high institutional ownership of 61.62%, reflecting confidence from larger investors.